- P-ISSN 1010-0695
- E-ISSN 2288-3339
- Apply for Authority
- P-ISSN1010-0695
- E-ISSN2288-3339
Article Detail
Home > Article Detail
Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats
Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2017, v.38 no.2, pp.61-72
https://doi.org/10.13048/jkm.17018
&
(2017). Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats. Journal of Korean Medicine, 38(2), 61-72, https://doi.org/10.13048/jkm.17018
- Downloaded
- Viewed
Abstract
Objectives: The effects of Gamiondam-tang (GMODT) co-administration within 5min on the pharmacokinetics (PK) of tamoxifen were observed as a process of the comprehensive and integrative medicine, combination therapy of tamoxifen with GMODT to achieve synergic pharmacodynamics and reduce toxicity on the breast cancer. Methods: After 50mg/kg of tamoxifen treatment, GMODT 100mg/kg was administered within 5min. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMODT treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with tamoxifen single administered rats using noncompartmental pharmacokinetics data analyzer programs. Results: Co-administration with GMODT induced increased trends of plasma tamoxifen concentrations to 1hr after end of administration, and then showed decreased trends of plasma tamoxifen concentrations, and especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5hr after end of co-administration with GMODT and also related significant (p<0.05) decreases of AUC0-inf and MRTinf as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 10 mg/kg and GMODT 100 mg/kg within 5 min, in this experiment. Conclusion: Based on the results of the present study, it is considered that single co-administration GMODT within 5min significantly inhibited the oral bioavailability of tamoxifen through variable influences on the absorption and excretion of tamoxifen, can be influenced on the toxicity or pharmacodynamic of tamoxifen.
- keywords
- Gamiondam-tang, Tamoxifen, Pharmacokinetics, Drug-drug interactions, Rat
Reference
1
1. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England journal of medicine. 2009;361(8):766-76.
2
2. Jordan VC, Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. British journal of pharmacology. 1993;110(2):507-17.
3
3. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British journal of pharmacology. 2006;147 Suppl 1:S269-76.
4
4. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Human reproduction (Oxford, England). 2005;20(6): 1511-5.
5
5. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Annals of internal medicine. 2006;144(2):101-6.
6
6. Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, et al., Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. Journal of clinical oncology :official journal of the American Society of Clinical Oncology. 2005;23(4):808-15.
7
7. Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. European urology. 2007;52(1):106-14.
8
8. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology. 2007;55(3-4): 123-31.
9
9. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, et al. Double -blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of affective disorders. 2011;129(1-3):327-31.
10
10. Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6(11):4359-64.
11
11. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P. Ligand-activated site-specific recombination in mice. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(20):10887-90.
12
12. Dabelic N, Jukic T, Labar Z, Novosel SA, Matesa N, Kusic Z. Riedel's thyroiditis treated with tamoxifen. Croatian medical journal. 2003;44(2):239-41.
13
13. Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. Thyroid : official journal of the American Thyroid Association. 2011;21(7):765-72.
14
14. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. Journal of pediatric endocrinology &metabolism : JPEM. 1999;12(5):681-6.
15
15. Sawathiparnich P, Osuwanaratana P, Santiprabhob J, Likitmaskul S. Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review. Journal of pediatric endocrinology & metabolism : JPEM. 2006;19(1):81-6.
16
16. Redmond CK, Costantino JP. Design and current status of the NSABP breast cancer prevention trial. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1996;140:309-17.
17
17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90(18):1371-88.
18
18. Lerner HJ, Band PR, Israel L, Leung BS, Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer treatment reports, 1976; 60(10):1431-5.
19
19. Pienta KJ, Redman BG, Esper PS, Flaherty LE. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone -refractory adenocarcinoma of the prostate. American journal of clinical oncology. 1996;19(5):500-3.
20
20. Zeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) prescribing information. 1998.
21
21. Kelly HL, Collichio FA, Dees EC. Concomitant pregnancy and breast cancer: options for systemic therapy. Breast disease. 2005;23:95-101.
22
22. Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. The oncologist. 2011;16(11):1547-51.
23
23. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast cancer research and treatment. 2008;107(2):167-80.
24
24. Karn A, Jha AK, Shrestha S, Acharya B, Poudel S, Bhandari RB. Tamoxifen for breast cancer. JNMA; journal of the Nepal Medical Association. 2010;49(177):62-7.
25
25. Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, Shibutani S. a-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chemical research in toxicology. 2003;16(9):1138-44.
26
26. Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a,4-dihydroxy derivatives. Chemical research in toxicology. 2005;18(10):1611-8.
27
27. Lien EA, Anker G, Lønning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer research. 1990;50(18):5851-7.
28
28. Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. BMJ (Clinical research ed.). 1989;298(6682):1253.
29
29. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ (Clinical research ed.). 1989;298(6666):93.
30
30. Lamberts SW, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. The Journal of clinical endocrinology and metabolism. 1986;63(6):1342-7.
31
31. Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999;5(9):2338-43.
32
32. Reid AD, Horobin JM, Newman EL, Preece PE. Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast cancer research and treatment. 1992;22(2):153-6.
33
33. Dehal SS, Brodie AM, Kupfer D. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A)inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug metabolism and disposition: the biological fate of chemicals. 1999;27(3):389-94.
34
34. West CM, Reeves SJ, Brough W. Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer letters. 1990;55(2):159-63.
35
35. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug metabolism and disposition: the biological fate of chemicals. 1993;21(4):645-56.
36
36. Mani C, Pearce R, Parkinson A, Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 1994;15(12):2715-20.
37
37. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug metabolism and disposition:the biological fate of chemicals. 2002;30(8):883-91.
38
38. Kwak MA, Park SJ, Park SH, Lee YJ, Ku SK. Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) -Single Oral Combination Treatment of Tamoxifen 50mg/kg with JEKHT 100mg/kg within 5min -. J Korean Med. 2016;37(2):1-11.
39
39. Park SJ, Kwak MA, Park SH, Lee YJ, Ku SK. Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated. J Soc Prev Korean Med. 2016;20(2):97-109.
40
40. Nakagawasai O, Yamadera F, Iwasaki K, Arai H, Taniguchi R, Tan-No K, et al. Effect of kami-untan-to on the impairment of learning and memory induced by thiamine-deficient feeding in mice. Neuroscience. 2004;125(1):233-41.
41
41. Oh HK, Park SJ, Bae SG, Kim MJ, Jang JH, Ahn YJ, et al. Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice. Journal of ethnopharmacology. 2013;146(2):600-7.
42
42. Wang Q, Iwasaki K, Suzuki T, Arai H, Ikarashi Y, Yabe T, et al. Potentiation of brain acetylcholine neurons by Kami-Untan-To (KUT)in aged mice: implications for a possible antidementia drug. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2000;7(4):253-8.
43
43. Nakagawasai O, Yamadera F, Iwasaki K, Asao T, Tan-No K, Niijima F, et al. Preventive effect of kami-untan-to on performance in the forced swimming test in thiamine-deficient mice:relationship to functions of catecholaminergic neurons. Behavioural brain research. 2007;177(2):315-21.
44
44. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Taylor & Francis. 1982.
45
45. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. Journal of pharmacokinetics and biopharmaceutics. 1988;16(3):303-9.
46
46. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. Journal of pharmacokinetics and biopharmaceutics. 1978;6(6):539-46.
47
47. Adam HK, Gay MA, Moore RH. Measurement of tamoxifen in serum by thin-layer densitometry. The Journal of endocrinology. 1980;84(1):35-42.
48
48. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer treatment reports. 1980;64(6-7):761-4.
49
49. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer treatment reports. 1980;64(6-7):765-73.
50
50. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer research. 1983;43(3):1446-50.
51
51. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). Journal of steroid biochemistry. 1987;26(5):547-55.
52
52. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast cancer research and treatment. 1982;2(2):123-38.
53
53. Sun D, Sharma AK, Dellinger RW, Blevins -Primeau AS, Balliet RM, Chen G, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug metabolism and disposition: the biological fate of chemicals. 2007;35(11):2006-14.
54
54. AstraZeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) prescribing information. 2003.
55
55. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. Journal of neuro-oncology. 2006;77(3):279-84.
56
56. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(4):675-80.
57
57. Grilli S. Tamoxifen (TAM): the dispute goes on. Annali dell'Istituto superiore di sanita. 2006;42(2):170-3.
58
58. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111(5):650-6.
59
59. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced non-alcoholic steatohepatitis:where are we now and where are we going? Expert opinion on drug safety. 2007;6(1):1-4.
60
60. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast cancer research and treatment. 2000;64(2):165-76.
61
61. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage. 2004;21(1):364-71.
62
62. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(5):1488-92.
63
63. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast cancer research and treatment. 2006;100(3):273-84.
64
64. Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, et al. Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2008;23(8):1267-77.
65
65. Wilson SC, Knight PG, Cunningham FJ. Evidence for the involvement of central conversion of testosterone to oestradiol-17b in the regulation of luteinizing hormone secretion in the cockerel. The Journal of endocrinology. 1983;99(2):301-10.
66
66. Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. Journal of immunology (Baltimore, Md. : 1950). 2005;175(4):2666-75.
67
67. Berstein LM, Wang JP, Zheng H, Yue W, Conaway M, Santen RJ. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(4):1530-4.
68
68. Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Annals of oncology :official journal of the European Society for Medical Oncology / ESMO. 2009;20(7):1281-2.
- Downloaded
- Viewed
- 0KCI Citations
- 0WOS Citations
Other articles from this issue
- Beneficial Effects of Natural Environment Therapy for Atopic Dermatitis
- Inhibition of mTOR signaling pathway by aqueous extract of Siberian ginseng
- Sub-acute toxicity and effect of Hwangryunhaedok-tang on human drug-metabolizing enzymes
- Effect of acupuncture on memory function in old rats
- Effect of Skin Lipid Barrier Formation on Hataedock Treatment with Douchi
- Beakdugu-tang, Traditional Korean Digestant Medicine, Inhibits Hepatic Steatosis in Insulin Resistance Cell Model with HepG2 and THP-1
- Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats
- Case Report for a Refractory Levator Ani Syndrome Treated with Traditional Korean Medication
- Improvement of Pneumonia in a Patient with Non-Small Cell Lung Cancer Treated with Herbal Medicine after Cessation of Antibiotics – a Case Report
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.